Antibe Therapeutics Inc (CVE:ATE) Senior Officer Scott Wilson Curtis acquired 30,000 shares of the stock in a transaction dated Monday, September 21st. The stock was bought at an average cost of C$0.35 per share, with a total value of C$10,500.00. Following the completion of the purchase, the insider now owns 309,000 shares of the company’s stock, valued at C$108,150.
Shares of ATE opened at C$0.34 on Friday. The company has a current ratio of 6.55, a quick ratio of 5.84 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $109.70 million and a price-to-earnings ratio of -4.59. The stock has a 50 day moving average of C$0.39 and a 200 day moving average of C$0.56. Antibe Therapeutics Inc has a 12 month low of C$0.33 and a 12 month high of C$0.89.
Antibe Therapeutics (CVE:ATE) last issued its quarterly earnings results on Monday, August 24th. The company reported C($0.02) EPS for the quarter, meeting the Zacks’ consensus estimate of C($0.02). The business had revenue of C$1.23 million for the quarter, compared to analysts’ expectations of C$2.25 million. As a group, equities research analysts predict that Antibe Therapeutics Inc will post -0.05 earnings per share for the current year.
Several analysts have recently commented on the company. Brookline Capital Management reissued a “buy” rating on shares of Antibe Therapeutics in a research note on Wednesday, July 15th. Maxim Group set a C$1.00 price objective on Antibe Therapeutics and gave the stock a “buy” rating in a research note on Thursday. Finally, Canaccord Genuity set a C$1.50 price objective on Antibe Therapeutics and gave the stock a “speculative buy” rating in a research note on Monday, August 17th.
About Antibe Therapeutics
Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study.
Recommended Story: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.